C Diff Resistance to Bacitracin Reveals Potential Drug Target

Investigators at Vanderbilt University Medical Center have identified a previously uncharacterized bacterial defense system in Clostridioides difficile that couples the pathogen's response to host iron restriction with its resistance to bacitracin, an antimicrobial produced by the gut commensal Bacillus licheniformis. The findings, published in Science Signaling, describe a 6-component "Bce module" that may represent a potential therapeutic target in an organism for which treatment options remain limited.

"C diff evolved to sense both stressors independently and collectively," Martin Douglass, PhD, first author and postdoctoral fellow in the lab of senior author Eric Skaar, PhD, MPH, said in a statement.

Bce Module Drives Bacitracin Resistance in C Difficile

C difficile is a leading cause of hospital-acquired infection in the United States, with more than 200,000 hospital-associated infections occurring annually, according to the study authors. People taking antibiotics, those recently hospitalized or living in a health care facility, and adults older than 65 years are at greatest risk. Treatment options remain limited. Using CRISPR mutagenesis in the CD196 strain, investigators characterized a genetic cluster encoding a 2-component sensor system (BceS and BceR), an adenosine triphosphate–binding cassette efflux pump (BceA and BceB), and an undecaprenyl pyrophosphatase (BacA2) that together mediate the response to bacitracin.

Deletion of bceS, bceR, or bceB impaired growth in the presence of bacitracin, while complementation restored growth. Bacitracin exposure increased transcription of bceB, bceA, and bacA2 more than 1000-fold in wild-type bacteria, an effect that was dependent on BceS and BceR. Investigators noted that this represents, to their knowledge, the first description of a Bce module that has incorporated an undecaprenyl pyrophosphatase as an accessory component.

Iron Restriction Increases C Difficile Susceptibility to Bacitracin

The investigators also found that expression of the module is repressed by Fur, the bacterium's principal iron-responsive transcriptional regulator. Because host neutrophils deploy the metal-sequestering protein calprotectin as part of nutritional immunity during infection, iron-limited conditions relieved Fur repression and increased transcription of the module independent of bacitracin exposure.

Liquid chromatography–mass spectrometry showed that iron chelation reduced undecaprenyl phosphate levels by approximately 50%. Because iron-dependent enzymes contribute to synthesis of this lipid carrier, the authors proposed that iron starvation reduces the available carrier pool and increases C difficile susceptibility to bacitracin, which targets undecaprenyl pyrophosphate and interferes with carrier recycling during cell wall synthesis.

Investigators reported that bacitracin and iron chelation produced additive or synergistic growth defects in wild-type bacteria, with a greater effect observed in phosphatase-deficient mutants. The findings support a model in which low iron and bacitracin act as independent but converging stressors on cell envelope maintenance.

Bacitracin Clears Bce Module-Deficient C Difficile in Mouse Model

In a cefoperazone-treated mouse model of C difficile infection, bacitracin administered in drinking water reduced fecal bacterial burden and protected against weight loss and mortality in mice infected with wild-type spores, though it did not clear the infection. In mice infected with a mutant lacking both bacA2 and bceB, bacitracin treatment resulted in undetectable bacterial burden and complete survival.

The investigators concluded that the Bce module helps wild-type C difficile withstand bacitracin exposure that would otherwise be more detrimental to the pathogen, positioning the module as a potential target for adjunctive therapy.

Douglass and colleagues described the Bce module as "an attractive therapeutic target," reasoning that inhibiting it could restore bacitracin sensitivity and allow the antibiotic to both neutralize the pathogen and clear infection.

The study authors noted that B licheniformis has been identified in human fecal samples and has shown activity against C difficile in prior work, including preservation of gut microbiota during vancomycin treatment and reduction of antibiotic-associated diarrhea in separate trials. However, bacitracin production or quantification in the human gut itself has not been directly measured. Douglass suggested B licheniformis could be explored as a probiotic option for patients at elevated risk for infection, and that agents targeting the newly identified system might eventually be developed for use alongside the bacterium.

Strain-Specific Findings Raise Generalizability Questions

The described mechanism was characterized primarily in a single C difficile strain (CD196), and the investigators noted that transposon sequencing data from a different strain (R20291) suggested differences in cell envelope maintenance between strains, which may limit generalizability. Whether inhibiting the Bce module is feasible as a druggable strategy, and how BacA2 physically interacts with the sensor-transporter complex, remain unresolved questions for future study.

References

1. Douglass MV, Melton LR, Calcutt MW, et al. Clostridioides difficile couples responses to host nutritional immunity and a commensal-derived antibiotic to enable growth in the gut. Sci Signal. 2026;19(954). doi:10.1126/scisignal.aef8846

2. C diff coordinates threat response to survive in gut. News release. Vanderbilt University Medical Center; September 8, 2026